CASTRES, France, June 22, 2026
Laboratoires Pierre Fabre has received a major regulatory milestone with the European Commission approval of BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC). The approval establishes the regimen as the first and only BRAF-targeted therapy approved in the European Union for previously untreated patients with BRAFV600E-mutated metastatic colorectal cancer, addressing a significant unmet need in a patient population known to experience aggressive disease progression and poor clinical outcomes. The decision is supported by compelling results from the pivotal Phase 3 BREAKWATER trial, which demonstrated substantial improvements in objective response rate, progression-free survival, and overall survival compared with standard oxaliplatin-based chemotherapy regimens with or without bevacizumab. The approval marks a significant advancement in precision oncology and expands access to targeted treatment strategies for patients with one of the most challenging forms of colorectal cancer.
BREAKWATER Study Delivers Strong Survival and Response Benefits
The European Commission’s decision was based on data from the global Phase 3 BREAKWATER clinical trial, which evaluated BRAFTOVI in combination with cetuximab and mFOLFOX6 in patients with previously untreated BRAFV600E-mutated metastatic colorectal cancer. The study achieved both of its primary endpoints, demonstrating statistically significant and clinically meaningful improvements over standard chemotherapy approaches. Patients receiving the BRAFTOVI-based regimen achieved a median progression-free survival of 12.8 months, compared with 7.1 months for patients receiving chemotherapy with or without bevacizumab, representing a 47% reduction in the risk of disease progression or death.
Additionally, the treatment combination significantly improved objective response rates, with approximately 61% of patients responding to therapy, compared with 40% in the control arm. Confirmed overall response rates were even higher, reaching nearly 66% of treated patients, highlighting the regimen’s ability to induce meaningful tumor shrinkage and disease control. These outcomes reinforce the potential of precision medicine approaches in improving survival outcomes for patients with genetically defined colorectal cancers.
First-Line Targeted Therapy Addresses Critical Unmet Need
Advertisement
BRAFV600E-mutated metastatic colorectal cancer represents a distinct molecular subtype of colorectal cancer associated with aggressive tumor biology, limited responsiveness to conventional therapies, and historically poor prognosis. Until now, treatment options for newly diagnosed patients in Europe have been largely limited to chemotherapy-based approaches. The approval of BRAFTOVI in combination with cetuximab and FOLFOX introduces a targeted therapeutic strategy specifically designed to inhibit the BRAF signaling pathway, a key driver of tumor growth in these patients.
Pierre Fabre leadership emphasized that the approval provides physicians with an important new option capable of delivering improved clinical outcomes while advancing personalized treatment approaches. By directly targeting the underlying molecular abnormality driving disease progression, the regimen offers a more precise treatment strategy that aligns with the growing role of biomarker-guided oncology care.
Expanding Precision Oncology Across Europe
The approval further strengthens Pierre Fabre’s presence in the global oncology market and underscores the increasing importance of molecularly targeted therapies in colorectal cancer treatment. Colorectal cancer remains one of the most commonly diagnosed cancers worldwide and a leading cause of cancer-related mortality. As genomic testing becomes more widely integrated into clinical practice, therapies tailored to specific molecular alterations are transforming treatment paradigms and improving patient outcomes.
The availability of BRAFTOVI as a first-line option for BRAFV600E-mutated mCRC provides a new standard of care for eligible patients across Europe and reinforces the value of biomarker-driven treatment strategies. With strong efficacy data demonstrating improvements in survival and tumor response, the approval represents an important advancement in the effort to deliver more effective, personalized therapies to patients facing advanced colorectal cancer.
Source: Pierre Fabre press release
